<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Clinical approach to the male with delayed puberty

Rey, Rodolfo Alberto Icon; Grinspon, Romina Icon; Castro, Sebastián

Otros responsables

Fecha

11/2025

Editorial

Sociedade Brasileira de Endocrinologia e Metabologia

Revista

Archives of Endocrinology and Metabolism

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2359-3997

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Disorders of pubertal onset and progression are a common cause for referral to paediatric endocrinologists, with delayed puberty in males being particularly frequent. Pubertal development depends on the hypothalamic-pituitary-testicular (HPT) axis, which is established during fetal life and undergoes distinct phases: fetal androgen production, postnatal “minipuberty”, and reactivation during adolescence. Key regulators include GnRH neurons, Sertoli and Leydig cells, and biomarkers such as AMH, inhibin B, testosterone and INSL3. Puberty is marked clinically by testicular enlargement beyond 4 mL, usually at a median age of 11.5 years. Delayed puberty is defined as absence of testicular enlargement by age 14. The most common cause is self-limited delayed puberty (SLDP), often familial and benign. Functional hypogonadotropic hypogonadism due to chronic illness, and permanent central hypogonadism (congenital or acquired), account for additional cases. Congenital hypogonadotropic hypogonadism (CHH), including Kallmann syndrome, is frequently genetic, with variants in genes such as FGFR1, ANOS1 and GNRHR. Clinical assessment includes family history, growth patterns, and red flags such as micropenis, cryptorchidism or anosmia.

Colecciones

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by